newsfilter
← Latest News
GlobeNewswire·

Crescent Biopharma Announces Grants of Inducement Awards

  • Crescent Biopharma's Compensation Committee approved equity inducement options for one non-executive employee on November 2, 2026.
  • The grant consists of 11,775 ordinary shares under the 2025 Employment Inducement Incentive Award Plan.
  • The options have a 10-year term & an exercise price of $12.91 per share, reflecting the Nasdaq closing price on November 2, 2026.
  • Vesting begins with 25% of the shares on the first anniversary of the employee's start date, followed by monthly vesting of 1/48th of the shares.
  • This grant was material to the employee's acceptance of employment & complies with Nasdaq Listing Rule 5635(c)(4).
  • Crescent Biopharma is a clinical-stage oncology company developing a PD-1 x VEGF bispecific antibody & novel antibody-drug conjugates.